PPARD and metabolic disease: In summary, our data provide experimental evidence that 95EEAI is a natural PPARδ agonist that robustly induces genes involved in fatty acid metabolism and activates fatty acid oxidation in vitro and in vivo, suggesting its potential as interventive and preventive measures for the treatment of metabolic disorders.